Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003
- PMID: 15980367
- PMCID: PMC1168634
- DOI: 10.1128/AAC.49.7.2903-2913.2005
Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003
Abstract
Susceptibility testing results for Streptococcus pneumoniae isolates (n = 2,279) from eight European countries, examined in the PneumoWorld Study from 2001 to 2003, are presented. Overall, 24.6% of S. pneumoniae isolates were nonsusceptible to penicillin G and 28.0% were resistant to macrolides. The prevalence of resistance varied widely between European countries, with the highest rates of penicillin G and macrolide resistance reported from Spain and France. Serotype 14 was the leading serotype among penicillin G- and macrolide-resistant S. pneumoniae isolates. One strain (PW 158) showed a combination of an efflux type of resistance with a 23S rRNA mutation (A2061G, pneumococcal numbering; A2059G, Escherichia coli numbering). Six strains which showed negative results for mef(A) and erm(B) in repeated PCR assays had mutations in 23S rRNA or alterations in the L4 ribosomal protein (two strains). Fluoroquinolone resistance rates (levofloxacin MIC > or = 4 microg/ml) were low (Austria, 0%; Belgium, 0.7%; France, 0.9%; Germany, 0.4%; Italy, 1.3%; Portugal, 1.2%; Spain, 1.0%; and Switzerland, 0%). Analysis of quinolone resistance-determining regions showed eight strains with a Ser81 alteration in gyrA; 13 of 18 strains showed a Ser79 alteration in parC. The clonal profile, as analyzed by multilocus sequence typing (MLST), showed that the 18 fluoroquinolone-resistant strains were genetically heterogeneous. Seven of the 18 strains belonged to new sequence types not hitherto described in the MLST database. Europe-wide surveillance for monitoring of the further spread of these antibiotic-resistant S. pneumoniae clones is warranted.
Figures

Similar articles
-
Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).J Antimicrob Chemother. 2007 Oct;60(4):733-40. doi: 10.1093/jac/dkm273. Epub 2007 Aug 2. J Antimicrob Chemother. 2007. PMID: 17673477
-
Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.J Clin Microbiol. 2004 Nov;42(11):4980-7. doi: 10.1128/JCM.42.11.4980-4987.2004. J Clin Microbiol. 2004. PMID: 15528684 Free PMC article.
-
Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.Clin Microbiol Infect. 2010 Jul;16(7):973-8. doi: 10.1111/j.1469-0691.2009.02951.x. Epub 2009 Sep 23. Clin Microbiol Infect. 2010. PMID: 19778298
-
Macrolide resistance in Streptococcus pneumoniae: clonality and mechanisms of resistance in 24 countries.Curr Drug Targets Infect Disord. 2004 Sep;4(3):169-76. doi: 10.2174/1568005043340821. Curr Drug Targets Infect Disord. 2004. PMID: 15379728 Review.
-
The antimicrobial resistance profile of Streptococcus pneumoniae.Clin Microbiol Infect. 2009 Apr;15 Suppl 3:7-11. doi: 10.1111/j.1469-0691.2009.02724.x. Clin Microbiol Infect. 2009. PMID: 19366363 Review.
Cited by
-
Global fluoroquinolone resistance epidemiology and implictions for clinical use.Interdiscip Perspect Infect Dis. 2012;2012:976273. doi: 10.1155/2012/976273. Epub 2012 Oct 14. Interdiscip Perspect Infect Dis. 2012. PMID: 23097666 Free PMC article.
-
Pneumococcal virulence gene expression and host cytokine profiles during pathogenesis of invasive disease.Infect Immun. 2008 Feb;76(2):646-57. doi: 10.1128/IAI.01161-07. Epub 2007 Nov 26. Infect Immun. 2008. PMID: 18039836 Free PMC article.
-
Insight Into Resistance Phenotypes of Emergent Non 13-valent Pneumococcal Conjugate Vaccine Type Pneumococci Isolated From Invasive Disease After 13-valent Pneumococcal Conjugate Vaccine Implementation in France.Open Forum Infect Dis. 2016 Feb 2;3(1):ofw020. doi: 10.1093/ofid/ofw020. eCollection 2016 Jan. Open Forum Infect Dis. 2016. PMID: 26955644 Free PMC article.
-
Elderly patients with community-acquired pneumonia: optimal treatment strategies.Drugs Aging. 2011 Jul 1;28(7):519-37. doi: 10.2165/11591980-000000000-00000. Drugs Aging. 2011. PMID: 21721597 Review.
-
Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.J Clin Microbiol. 2006 Mar;44(3):970-5. doi: 10.1128/JCM.44.3.970-975.2006. J Clin Microbiol. 2006. PMID: 16517885 Free PMC article.
References
-
- Appelbaum, P. C. 2002. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin. Infect. Dis. 34:1613-1620. - PubMed
-
- Arbique, J. C., C. Poyart, P. Trieu-Cuot, G. Quesne, G. Carvalho Mda, A. G. Steigerwalt, R. E. Morey, D. Jackson, R. J. Davidson, and R. R. Facklam. 2004. Accuracy of phenotypic and genotypic testing for identification of Streptococcus pneumoniae and description of Streptococcus pseudopneumoniae sp. nov. J. Clin. Microbiol. 42:4686-4696. - PMC - PubMed
-
- Canton, R., M. Morosini, M. C. Enright, and I. Morrissey. 2003. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J. Antimicrob. Chemother. 52:944-952. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical